Generic placeholder image

Recent Patents on Anti-Cancer Drug Discovery

Editor-in-Chief

ISSN (Print): 1574-8928
ISSN (Online): 2212-3970

Molecularly Targeted Therapy in Breast Cancer: The New Generation

Author(s): Zeina A. Nahleh

Volume 3 , Issue 2 , 2008

Page: [100 - 104] Pages: 5

DOI: 10.2174/157489208784638794

Price: $65

Abstract

Breast cancer management has become increasingly complex, requiring the integration of data not only from the patients history and imaging modalities but also from specific tumor biomarkers and gene expression. Targeted and biologic therapies in breast cancer continue to evolve rapidly. The field of molecular targeted therapy has emerged. Its ultimate goal is to personalize and simplify treatment as well as minimize toxicity. This review aims at highlighting the current state-of-the-art in novel molecular targeted therapies for breast cancer based on multi-targeted small molecule tyrosine kinase inhibitors (TKI). The first two agents in this group entering clinic, Lapatinib (GW572016; Tykerb ®) and SUNITINIB (SU11248; Sutent®) are discussed. This review article also includes relevant patents.

Keywords: Multitargeted, small molecule, tyrosine kinase inhibitors, breast cancer


Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy